135 related articles for article (PubMed ID: 37530469)
21. Prediction of risk and clinical outcome of cuproptosis in lung squamous carcinoma.
Zhang Y; Zhou J; Li H; Liu Y; Li J
BMC Pulm Med; 2023 Jun; 23(1):205. PubMed ID: 37308925
[TBL] [Abstract][Full Text] [Related]
22. Construction of a Prognostic Model for Predicting Colorectal Cancer Prognosis and Response to Immunotherapy Based on Cuproptosis-Associated lncRNAs.
Yang Y; Wang X; Lu J; Dong Z; Hu R; Chen W; Hu S; Lu G; Huang B; Dong S; Wang L; Wang C
J Oncol; 2023; 2023():2733232. PubMed ID: 36968641
[TBL] [Abstract][Full Text] [Related]
23. Molecular subtypes based on cuproptosis-related genes and immune profiles in lung adenocarcinoma.
Wang Y; Zhang C; Ji C; Jin W; He X; Yu S; Guo R
Front Genet; 2022; 13():1006938. PubMed ID: 36313439
[No Abstract] [Full Text] [Related]
24. Impact of Cuproptosis-related markers on clinical status, tumor immune microenvironment and immunotherapy in colorectal cancer: A multi-omic analysis.
Shao Y; Fan X; Yang X; Li S; Huang L; Zhou X; Zhang S; Zheng M; Sun J
Comput Struct Biotechnol J; 2023; 21():3383-3403. PubMed ID: 37389187
[TBL] [Abstract][Full Text] [Related]
25. Identification of cuproptosis-related subtypes and development of a prognostic signature in colorectal cancer.
Huang Y; Yin D; Wu L
Sci Rep; 2022 Oct; 12(1):17348. PubMed ID: 36253436
[TBL] [Abstract][Full Text] [Related]
26. Identification of cuproptosis-related subtypes and characterization of the tumor microenvironment landscape in head and neck squamous cell carcinoma.
Huang J; Xu Z; Yuan Z; Cheng L; Zhou C; Shen Y
J Clin Lab Anal; 2022 Sep; 36(9):e24638. PubMed ID: 36082469
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive analysis of a cuproptosis-related ceRNA network implicates a potential endocrine therapy resistance mechanism in ER-positive breast cancer.
Zhang D; Lu W; Zhuo Z; Wang Y; Zhang W; Zhang M
BMC Med Genomics; 2023 May; 16(1):96. PubMed ID: 37143115
[TBL] [Abstract][Full Text] [Related]
28. Multiomics Analysis Reveals Cuproptosis-Related Signature for Evaluating Prognosis and Immunotherapy Efficacy in Colorectal Cancer.
He R; Zhang H; Zhao H; Yin X; Lu J; Gu C; Gao J; Xu Q
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672336
[TBL] [Abstract][Full Text] [Related]
29. Identification of cuproptosis-based molecular subtypes, construction of prognostic signature and characterization of immune landscape in colon cancer.
Wang X; Zuo X; Hu X; Liu Y; Wang Z; Chan S; Sun R; Han Q; Yu Z; Wang M; Zhang H; Chen W
Front Oncol; 2023; 13():927608. PubMed ID: 37007145
[TBL] [Abstract][Full Text] [Related]
30. Cuproptosis-related miRNAs signature and immune infiltration characteristics in colorectal cancer.
Zhu Z; Guo T; Weng J; Li S; Zhu C; Zhao Q; Xu Y
Cancer Med; 2023 Aug; 12(15):16661-16678. PubMed ID: 37334893
[TBL] [Abstract][Full Text] [Related]
31. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
32. Cuproptosis-related modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of kidney renal clear cell carcinoma.
Cai Z; He Y; Yu Z; Hu J; Xiao Z; Zu X; Li Z; Li H
Front Immunol; 2022; 13():933241. PubMed ID: 36211378
[TBL] [Abstract][Full Text] [Related]
33. Molecular subtypes of cuproptosis regulators and their correlation with clinical prognosis and immune response in glioma.
Zhang Y; Dai X; Li Z
Am J Transl Res; 2022; 14(11):8085-8102. PubMed ID: 36505293
[TBL] [Abstract][Full Text] [Related]
34. Development and validation of cuproptosis-related lncRNA signatures for prognosis prediction in colorectal cancer.
Pang L; Wang Q; Wang L; Hu Z; Yang C; Li Y; Wang Z; Li Y
BMC Med Genomics; 2023 Mar; 16(1):58. PubMed ID: 36949429
[TBL] [Abstract][Full Text] [Related]
35. Identification of immune infiltration and cuproptosis-related molecular clusters in tuberculosis.
Li S; Long Q; Nong L; Zheng Y; Meng X; Zhu Q
Front Immunol; 2023; 14():1205741. PubMed ID: 37497230
[TBL] [Abstract][Full Text] [Related]
36. Unraveling Colorectal Cancer and Pan-cancer Immune Heterogeneity and Synthetic Therapy Response Using Cuproptosis and Hypoxia Regulators by Multi-omic Analysis and Experimental Validation.
Jiang PC; Fan J; Zhang CD; Bai MH; Sun QQ; Chen QP; Mao W; Tang BF; Lan HY; Zhou YY; Zhu J
Int J Biol Sci; 2023; 19(11):3526-3543. PubMed ID: 37496994
[TBL] [Abstract][Full Text] [Related]
37. Cuproptosis patterns and tumor immune infiltration characterization in colorectal cancer.
Du Y; Lin Y; Wang B; Li Y; Xu D; Gan L; Xiong X; Hou S; Chen S; Shen Z; Ye Y
Front Genet; 2022; 13():976007. PubMed ID: 36176287
[TBL] [Abstract][Full Text] [Related]
38. Cuproptosis-Mediated Patterns Characterized by Distinct Tumor Microenvironment and Predicted the Immunotherapy Response for Gastric Cancer.
Wang XX; Deng SZ; Wu LH; Liu QQ; Zheng G; Du K; Dou QY; Zheng J; Zhang HM
ACS Omega; 2023 Mar; 8(12):10851-10862. PubMed ID: 37008098
[TBL] [Abstract][Full Text] [Related]
39. Integrated machine learning and bioinformatic analyses used to construct a copper-induced cell death-related classifier for prognosis and immunotherapeutic response of hepatocellular carcinoma patients.
Zhao S; Chen S; Liu W; Wei S; Wu X; Cui D; Jiang L; Chen S; Wang J
Front Pharmacol; 2023; 14():1188725. PubMed ID: 37266152
[No Abstract] [Full Text] [Related]
40. Identification of cuproptosis -related subtypes, the development of a prognosis model, and characterization of tumor microenvironment infiltration in prostate cancer.
Jin L; Mei W; Liu X; Sun X; Xin S; Zhou Z; Zhang J; Zhang B; Chen P; Cai M; Ye L
Front Immunol; 2022; 13():974034. PubMed ID: 36203594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
